James Cheng‐Chung Wei
James Cheng‐Chung Wei publishes mostly in Rheumatology, Epidemiology and Immunology, on topics such as Spondyloarthritis Studies and Treatments, Rheumatoid Arthritis Research and Therapies and Psoriasis: Treatment and Pathogenesis.
- World rank
- #924,481 of 7,710,434 ranked researchers
- Rank in Taiwan
- #4,290 of 57,035
- Works
- 1,013
- Citations
- 24k
- Citations per work
- 24.2
What does James Cheng‐Chung Wei research?
James Cheng‐Chung Wei's work is mostly in Medicine (30%), Immunology and Microbiology (5%), Biochemistry, Genetics and Molecular Biology (3%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else63362.5%
- Health Sciences29929.5%
- Medicine29929.5%
- Life Sciences818.0%
- 1Rheumatology16% of their works
- 2Epidemiology5% of their works
- 3Immunology5% of their works
- 4Surgery4% of their works
- 5Endocrinology, Diabetes and Metabolism4% of their works
- 6Molecular Biology3% of their works
Research topics
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Diabetes Treatment and Management
- Gout, Hyperuricemia, Uric Acid
- Liver Disease Diagnosis and Treatment
Which keywords describe James Cheng‐Chung Wei's research?
The keywords of their largest research topics: Autoantibodies, Cardiovascular Risk, Inflammation, Ankylosing Spondylitis, Spondyloarthritis, Biological Therapy, Rheumatoid Arthritis and IL-17.
- NASH
- Uric Acid
- Hyperuricemia
- Juvenile Idiopathic Arthritis
- Systemic Lupus Erythematosus
- Metabolic Syndrome
- IL-17
- Biological Therapy
- Ankylosing Spondylitis
- Cardiovascular Risk
- Autoantibodies
- Inflammation
- Spondyloarthritis
- Rheumatoid Arthritis
- TH17 Cells
- Antiphospholipid Syndrome
- Hemophagocytic Lymphohistiocytosis
- Cardiovascular Outcomes
- Type 2 Diabetes
- NAFLD
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 20 words, with their numbers
- Autoantibodies2262 topics
- Cardiovascular Risk2042 topics
- Inflammation2042 topics
- Ankylosing Spondylitis1701 topic
- Spondyloarthritis1701 topic
- Biological Therapy1661 topic
- Rheumatoid Arthritis1661 topic
- IL-17771 topic
- TH17 Cells771 topic
- Metabolic Syndrome732 topics
- Antiphospholipid Syndrome601 topic
- Systemic Lupus Erythematosus601 topic
- Hemophagocytic Lymphohistiocytosis431 topic
- Juvenile Idiopathic Arthritis431 topic
- Cardiovascular Outcomes381 topic
- Hyperuricemia381 topic
- Type 2 Diabetes381 topic
- Uric Acid381 topic
- NAFLD351 topic
- NASH351 topic
Where does James Cheng‐Chung Wei work?
James Cheng‐Chung Wei's main affiliation in the publication record is Chung Shan Medical University Hospital, Taiwan.
How many publications and citations does James Cheng‐Chung Wei have?
OpenAlex counts 1,013 works and 24,474 citations for James Cheng‐Chung Wei, an h-index of 62, ranking #924,481 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named James Cheng‐Chung Wei
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about James Cheng‐Chung Wei. Posts are plain text and can be reported.